CP
ALXN

Covenant Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Covenant Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,501
Closed -$459K – 205
2021
Q2 		$459K Hold
2,501
– – 0.17% 116
2021
Q1 		$382K Sell
2,501
-1,202
-32% -$186K 0.15% 135
2020
Q4 		$579K Hold
3,703
– – 0.25% 83
2020
Q3 		$424K Sell
3,703
-628
-15% -$67.7K 0.21% 110
2020
Q2 		$486K Sell
4,331
-111
-2% -$11.8K 0.23% 100
2020
Q1 		$399K Buy
4,442
+1,293
+41% +$127K 0.21% 105
2019
Q4 		$341K Buy
3,149
+1,011
+47% +$108K 0.16% 141
2019
Q3 		$209K Sell
2,138
-2,153
-50% -$243K 0.11% 169
2019
Q2 		$562K Buy
4,291
+578
+16% +$74.5K 0.3% 87
2019
Q1 		$502K Buy
+3,713
New +$462K 0.28% 96

Other funds holding ALXN

Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TD Ameritrade Investment Management
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Covenant Partners's ALXN Position: Q3 2021 in Review

Covenant Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,501 shares — an estimated $459K sold.

Covenant Partners first reported a position in ALXN in Q1 2019 and held it in 10 quarters. The position peaked at $579K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Covenant Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Covenant Partners sold 2,501 Alexion Pharmaceuticals shares in Q3 2021, an estimated $459K.
  • Covenant Partners first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • Covenant Partners's Alexion Pharmaceuticals position peaked at $579K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Covenant Partners's 13F filing for Q3 2021, filed 12 Nov 2021.